Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: TG6002

Bioavailability and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas

P. Cassier et al. ESMO 2021 Download the poster here Poster Presentation

Published 16 September 2021
Categorized as -others, 2021, Publication, TG6002

Transgene presents data from Phase I clinical trial confirming the potential of the oncolytic virus TG6002

Transgene presents data from Phase I clinical trial confirming the potential of the oncolytic virus TG6002

Published 16 September 2021
Categorized as 2021, Press release, TG6002

3D organoids derived from patients’ lung tumors: a tool for investigating the potential of oncolytic viruses

Poster BT-001 Hélène Lê et al. EUROoCS 2021 Download the Poster here Poster Presentation

Published 1 July 2021
Categorized as -others, -others, 2021, BT-001, Publication, TG6002

Oncolytic virus TG6002 locates to tumors after intravenous infusion and induces tumor-specific expression of a functional pro-drug activating enzyme in patients with advanced gastrointestinal carcinomas

K. Bendjama et al. AACR 2021 Read the abstract here – Download the poster here Poster Presentation

Published 9 April 2021
Categorized as -others, 2021, Invir.IO, Publication, TG6002

Transgene presents initial Phase I data of TG6002, highlighting the potential of the intravenous administration of its oncolytic viruses

20210409 – TG6002 AACR EN

Published 9 April 2021
Categorized as -others, 2021, Press release, TG6002

Safety, biodistribution and viral shedding of oncolytic vaccinia virus TG6002 administered intravenously in healthy beagle dogs

Jérémy Béguin, et al. Sci Rep., January 26 2021 – Read the article Publication

Published 26 January 2021
Categorized as -others, 2021, Publication, TG6002

Positive initial data from a Phase 1 trial with Transgene’s oncolytic virus TG6002

20200908 Transgene TG6002 Phase 1 EN

Published 8 September 2020
Categorized as -others, 2020, Invir.IO, Press release, TG6002

Preclinical Evaluation of the Oncolytic Vaccinia Virus TG6002 by Translational Research on Canine Breast Cancer

Jérémy Béguin, et al.Molecular Therapy Oncolytics, September 2020 – Read the articlePublication

Published 2 September 2020
Categorized as 2020, Publication, TG6002

Safety studies and viral shedding of intramuscular administration of oncolytic vaccinia virus TG6002 in healthy beagle dogs

Jérémy Béguin, et al.BMC Vet Res., August 25 2020 – Read the articlePublication

Published 25 August 2020
Categorized as -others, 2020, Publication, TG6002

First Patient Dosed with Transgene’s Oncolytic Virus TG6002, Administered by Intrahepatic Artery Infusion in Colorectal Cancer with Liver Metastases

20200220 PR FPI 6002.03 EN

Published 20 February 2020
Categorized as 2020, Press release, TG6002

Posts pagination

Newer posts Page 1 Page 2 … Page 4 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu